Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Open-Label, Multicenter Study to Characterize the Safety and Tolerability of CFT8634 in Subjects With Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors
Conditions
Interventions
CFT8634
Locations
12
United States
City of Hope
Duarte, California, United States
Sarcoma Oncology Research Center
Santa Monica, California, United States
University of Colorado - Aurora Cancer Center
Aurora, Colorado, United States
Mayo Clinic - Jacksonville
Jacksonville, Florida, United States
University of Iowa Hospital and Clinics
Iowa City, Iowa, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Start Date
March 25, 2022
Primary Completion Date
December 19, 2023
Completion Date
December 19, 2023
Last Updated
December 17, 2024
NCT07156565
NCT02701153
NCT07432932
NCT07222735
NCT06500065
NCT06797999
Lead Sponsor
C4 Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions